Acromegaly and Gigantism

Acromegaly and gigantism represent chronic endocrine disorders caused by excessive growth hormone (GH) secretion, resulting in pathologic skeletal and soft tissue growth. Gigantism occurs when GH excess develops before epiphyseal plate closure (typically in childhood/adolescence), manifesting as abnormal linear growth, while acromegaly develops in adults after skeletal maturity, causing enlargement of distal extremities, facial features, and internal organs. The incidence of acromegaly is approximately 3–4 cases per million population annually with a prevalence of 40–70 cases per million, though these figures likely underestimate disease burden due to diagnostic delays averaging 5–10 years. Over 95% of cases result from pituitary adenomas, particularly growth hormone-secreting somatotroph adenomas, making this a critical diagnosis for practicing physicians to recognize early. Untreated acromegaly increases mortality 2–3 fold primarily through cardiovascular complications, malignancy, and respiratory disease, underscoring the importance of prompt recognition and management in clinical practice and board examinations.

Growth hormone is synthesized by somatotroph cells comprising approximately 50% of anterior pituitary cells and is controlled by a dual hypothalamic regulatory system. GH-releasing hormone (GHRH) stimulates GH secretion while somatostatin (SRIF) inhibits it; in acromegaly, this physiologic feedback control is disrupted by autonomous GH production. In normal physiology, elevated free insulin-like growth factor-1 (IGF-1) provides negative feedback to suppress both hypothalamic GHRH and pituitary GH secretion; however, GH-secreting adenomas escape this feedback mechanism and continue autonomous hormone production despite elevated IGF-1 levels.

GH exerts dual mechanisms of action: direct effects via GH receptors on target tissues (acute metabolic effects including lipolysis and insulin antagonism) and indirect effects mediated through IGF-1, which is produced predominantly in the liver and acts endocrine fashion on distant tissues, as well as locally produced IGF-1 in skeletal and soft tissues. IGF-1 drives the majority of GH's anabolic and growth-promoting effects through activation of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase, resulting in increased protein synthesis, increased glucose uptake, enhanced collagen deposition, and accelerated bone turnover. Chronically elevated IGF-1 (the best marker of GH action) causes progressive skeletal growth including jaw prognathism, frontal bossing, increased shoe and glove size, and organomegaly (heart, liver, kidneys). The degree of IGF-1 elevation correlates with disease severity and complications.

Most GH-secreting adenomas (approximately 40% of all pituitary adenomas) are benign monoclonal tumors derived from a single transformed somatotroph cell, though rare aggressive or malignant variants exist. These adenomas typically result from somatic mutations in GNAS (encoding Gs-alpha protein) in approximately 40% of cases, leading to constitutive activation of cAMP signaling and relentless GH transcription and secretion independent of physiologic inhibitory signals. Less commonly, mutations in other oncogenic pathways (AIP gene loss in familial acromegaly, mutations in PRKAR1A) predispose to adenoma formation. Adenoma growth is slow but progressive; approximately 35% of adenomas are macroadenomas (>10 mm) at diagnosis with potential for mass effects (visual field defects from optic chiasm compression, hypopituitarism from compression of other cell lines, headache from traction on dura).

Chronic GH/IGF-1 excess produces profound metabolic derangements: insulin resistance develops through GH's anti-insulin effects and impaired insulin secretion, resulting in frank diabetes mellitus in 10–25% of patients and impaired glucose tolerance in another 25%; hypertension occurs in 30–50% of patients through multiple mechanisms including sodium retention, increased sympathetic tone, and vascular smooth muscle proliferation. Dyslipidemia with elevation of triglycerides and reduction of HDL is nearly universal. Accelerated atherosclerosis, cardiomegaly with concentric left ventricular hypertrophy, and diastolic dysfunction occur from combined effects of GH, IGF-1, insulin resistance, and hypertension. Increased bone turnover with accelerated osteoclastic and osteoblastic activity leads to osteoporosis or osteopenia despite increased bone mass (paradoxical decrease in bone quality), increasing fracture risk. Soft tissue proliferation affects virtually all organs: acanthosis nigricans, skin tags, hyperhydrosis (from sweat gland hyperplasia), thyroid enlargement (in 50%), and arthropathy from cartilage proliferation and degenerative changes.

Increased cancer risk in acromegaly (approximately 2–3 fold elevation) results from both direct IGF-1 mitogenic effects promoting cell proliferation and potential effects of GH on immune surveillance; colorectal polyps and cancer are particularly common and warrant screening, as are benign skin neoplasms (nevi, seborrheic keratoses).

GH-secreting somatotroph adenomas account for the overwhelming majority of acromegaly cases. Most are sporadic, but approximately 5% are familial, occurring in context of multiple endocrine neoplasia type 1 (MEN-1) syndrome (associated with MENIN gene mutation), familial isolated pituitary adenoma (FIPA) associated with AIP gene mutations, or Carney complex (PRKAR1A mutations). Adenomas range from microadenomas (<10 mm, rare in acromegaly as these typically produce insufficient GH) to large invasive macroadenomas with suprasellar and lateral extension. Adenoma size, growth rate, and invasiveness vary widely and influence treatment decisions and prognosis.

Approximately 40% of GH-secreting adenomas harbor activating point mutations in GNAS (guanine nucleotide-binding protein, alpha-stimulating activity polypeptide), encoding the stimulatory G protein (Gs-alpha) coupled to GH-releasing hormone receptor. These mutations (most commonly arginine-201 to cysteine/histidine substitutions) cause constitutive activation of adenylyl cyclase and cAMP signaling, leading to uncontrolled GH transcription and proliferation. Presence of GNAS mutations correlates with certain clinical phenotypes (larger adenomas in some studies, though data are mixed).

Ectopic GHRH secretion from neuroendocrine tumors (carcinoid tumors, pancreatic neuroendocrine tumors, small cell lung cancer, medullary thyroid carcinoma, pheochromocytoma) drives pituitary somatotroph hyperplasia and secondary GH overproduction, representing approximately 0.5–1% of acromegaly cases. Ectopic GH secretion from non-pituitary sources (lung carcinoma, breast cancer, pancreatic tumors, ovarian tumors) is extremely rare but documented; these tumors produce authentic GH or incompletely processed GH precursors. Diagnosis of ectopic etiology requires imaging to localize the source and may necessitate more aggressive systemic treatment.

Multiple endocrine neoplasia type 1 (MEN-1) and familial isolated pituitary adenoma (FIPA) substantially increase lifetime risk of pituitary adenomas including GH-secreting variants; patients with MEN-1 or FIPA warrant heightened surveillance and early genetic testing.

Patients characteristically report progressive increase in glove size, shoe size, and ring size, often spanning years before diagnosis. Facial features become progressively coarser with frontal bossing (prominent supraorbital ridges), prognathism (mandibular overgrowth with characteristic underbite and malocclusion), widening of the nasal bridge, enlargement of ears, and deepening of nasolabial folds and forehead wrinkles. These changes result from periosteal bone proliferation and soft tissue hyperplasia. Photographs spanning years often provide dramatic documentation of progressive change and are invaluable diagnostically when reviewing old driver's licenses or family pictures.

Hepatomegaly occurs in approximately 20% of patients from GH-stimulated hepatocyte hypertrophy; thyroid enlargement (goiter) develops in approximately 50%, though thyroid function typically remains normal; cardiac hypertrophy with cardiomegaly is nearly universal histologically, though clinical symptoms may be absent early. Renal enlargement, splenic enlargement, and thickened skin (measured by skin fold calipers) are common. Patients may report progressive tightness of rings, dentures, or shoes; women may note worsening of shoe fit before recognition of other changes.

Overt diabetes develops in approximately 10–25% of patients due to GH-induced insulin resistance and beta-cell exhaustion; another 25% develop impaired fasting glucose or impaired glucose tolerance. Notably, patients with acromegaly-associated diabetes often have less peripheral neuropathy and retinopathy than primary diabetics, attributed to better insulin secretion and less severe hyperglycemia despite insulin resistance. Testing for hyperglycemia is essential at diagnosis and during follow-up.

Hypertension occurs in 30–50% of acromegalic patients from sodium retention, increased sympathetic tone, and increased peripheral vascular resistance; it is often resistant to single-agent therapy. Concentric left ventricular hypertrophy and diastolic dysfunction develop from chronic GH/IGF-1 exposure and hemodynamic burden of hypertension and diabetes, manifesting as dyspnea on exertion, orthopnea, or fatigue. Systolic dysfunction occurs in more advanced disease. Coronary artery disease is accelerated. Arrhythmias including atrial fibrillation develop in approximately 5–10% of patients from atrial enlargement and increased automaticity; sudden cardiac death has been documented. Echocardiographic assessment is warranted at diagnosis and periodically during follow-up.

Approximately 50% of patients develop joint pain and stiffness, particularly in large joints (hips, knees, shoulders, elbows) and the spine, resulting from cartilage proliferation and degenerative osteoarthropathy. Hypertrophic osteoarthropathy with periosteal proliferation at long bone metaphyses can be dramatic on radiographs. Bone mineral density is often increased (higher total bone mass) despite paradoxical architectural deterioration and increased fracture risk, particularly in the spine (osteoporotic vertebral compression fractures despite high bone density measures). Spinal stenosis and radiculopathy from osteophyte formation and cartilage proliferation can cause significant disability.

Increased cancer incidence (particularly colorectal cancer which occurs in approximately 5–10% of acromegalic patients compared to 3–4% in general population, and skin cancers including melanoma) mandates colonoscopy screening and dermatologic surveillance.

Obstructive sleep apnea develops in approximately 40–80% of patients from pharyngeal soft tissue proliferation, tongue enlargement, and upper airway narrowing. Sleep apnea contributes significantly to mortality and morbidity through recurrent hypoxemia, fragmented sleep, and sudden cardiac death. Patients should be questioned about snoring, witnessed apneas, daytime somnolence, and morning headaches; polysomnography is indicated and continuous positive airway pressure (CPAP) or BiPAP therapy should be offered. Central sleep apnea can also occur from posterior pituitary involvement or medullary respiratory center effects.

Headaches occur in approximately 50–70% of acromegalic patients, attributed to stretching of the dura mater and/or adenoma mass; headaches are often described as frontal or temporal, may be severe, and sometimes improve after transsphenoidal surgery. Larger macroadenomas can compress the optic chiasm, causing bitemporal hemianopsia (typically superior temporal field loss first due to compression from below), visual blurring, or other field defects; pituitary apoplexy with acute expansion of adenoma (from hemorrhage or infarction) presents with sudden headache, vision loss, ophthalmoplegia, and potential cardiovascular collapse.

Large adenomas can compress and destroy adjacent pituitary cells, causing secondary deficiencies in other pituitary hormones; secondary hypothyroidism and secondary hypogonadism are common, with men reporting erectile dysfunction and decreased libido, and women experiencing amenorrhea or oligomenorrhea. Secondary adrenal insufficiency may develop silently and be unmasked by stress or surgery, necessitating careful assessment and perioperative steroid coverage.

In addition to simple goiter (typically without functional impairment), autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis) occur with increased frequency in acromegaly, possibly from immune dysregulation.

Mood disturbances (depression, anxiety) occur in approximately 10–15% of patients, potentially from adenoma mass effects, metabolic derangements, or psychosocial impact of disfiguring disease. Cognitive changes including memory impairment and mood lability have been reported.

Acanthosis nigricans (dark, velvety plaques typically in intertriginous areas) occurs from IGF-1-induced skin proliferation and is associated with insulin resistance. Skin tags (acrochordons) are nearly universal and may number in the dozens. Seborrheic keratoses, nevi, and other benign skin neoplasms proliferate. Hyperhydrosis (excessive sweating) from sweat gland hyperplasia causes discomfort and social distress.

Silent somatotroph adenomas (producing GH without clinical manifestations) are extremely rare; however, oligosymptomatic disease is common due to diagnostic delays. Aggressive adenomas with rapid growth, local invasion, or recurrence after surgery are seen in approximately 10–15% of cases. Macroadenomas presenting with mass effects but minimal metabolic symptoms can be missed if GH/IGF-1 levels are not checked in patients with pituitary adenomas and headaches.

The diagnosis of acromegaly should be considered in any patient presenting with progressive coarsening of facial features, acral enlargement, carpal tunnel syndrome, sleep apnea, hypertension with diabetes, or pituitary adenoma on imaging. Historical documentation of progressive change (old photographs, reports of increasing glove/shoe size, dental malocclusion) provides strong supportive evidence. Physical examination should focus on facial coarsening, prognathism, acral size, skin changes (tags, acanthosis nigricans), organomegaly, hypertension, and signs of hypopituitarism.

A single random GH level >1 ng/mL in a patient with clinical suspicion warrants further investigation, though GH is secreted in a pulsatile fashion with significant variability; a normal single GH level does not exclude acromegaly. Conversely, random GH >10 ng/mL in conjunction with elevated IGF-1 is highly suggestive of acromegaly. GH assays vary between laboratories (reference ranges typically <0.4–4 ng/mL in fasting state in non-acromegalic individuals), necessitating interpretation with knowledge of the assay used.

IGF-1 is the most useful diagnostic marker because it reflects integrated GH action over 24 hours and demonstrates less pulsatile variation than GH itself; IGF-1 is age- and sex-adjusted. A

Goals of therapy (Endocrine Society Clinical Practice Guideline on Acromegaly; Pituitary Society consensus): normalize age- and sex-adjusted IGF-1, suppress GH (random GH in the low range, with failure to suppress on OGTT no longer present), remove or control tumor mass, preserve residual pituitary function, and reverse comorbidity.

Neoplastic and musculoskeletal: IGF-1 mitogenesis raises colorectal neoplasia risk (colonoscopy at diagnosis per Endocrine Society); arthropathy, spinal stenosis, and vertebral fractures despite high measured bone density; bilateral carpal tunnel syndrome from median nerve entrapment.